SCHEMBL4418783

SCHEMBL4418783

O=S(=O)(c1ccc(Oc2cccnc2)cc1)N1CC2C([CH]c3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 3/20 0.42
MEN1 O00255 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.37
MMP1 P03956 2/20 0.37
MMP13 P45452 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM1A O60341 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MMP2 P08253 1/20 0.36
ADAM17 P78536 1/20 0.36
GAA P10253 1/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 2/20 0.35
PIK3CA P42336 1/20 0.35
NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4431014 0.91 LMNA (0.43) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4421900 0.86 LMNA (0.40) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4424440 0.82 HSD11B1 (0.41) KMT2ASMN1; SMN2LMNAMEN1MAPT
SCHEMBL6509183 0.82 KMT2A (0.40) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL6509182 0.82 NAMPT (0.46) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4421354 0.80 SLC6A9 (0.43) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4420883 0.73 LMNA (0.45) SMN1; SMN2LMNAMAPTALDH1A1GAA
SCHEMBL4415378 0.73 HTT (0.45) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4425059 0.72 KMT2A (0.49) KMT2ASMN1; SMN2LMNAMEN1HTT
SCHEMBL4415375 0.72 HTT (0.53) KMT2ASMN1; SMN2LMNAMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 KMT2A 1892/4885SMN1; SMN2 4003/4885LMNA 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.